Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Company Deals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Fineline Cube Jun 16, 2026
Company Deals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Fineline Cube Jun 16, 2026
Company Deals

TriApex Laboratories Files for Hong Kong IPO – Next-Generation CRO with 240+ NMPA Approvals

Fineline Cube Jun 16, 2026
Company Deals

Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services

Fineline Cube Jun 15, 2026
Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026
Company Drug

BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications

Fineline Cube Jun 16, 2026
Company Drug

Gilead Sciences Submits sNDA for Once-Weekly Oral Yeztugo PrEP – Potential First Long-Acting Oral HIV Prevention Option

Fineline Cube Jun 16, 2026
Company Deals

Hainan Free Trade Port to Simplify Drug Import Procedures

Fineline Cube Nov 4, 2022

The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September...

Policy / Regulatory

Hainan Free Trade Port to Simplify Drug Import Procedures

Fineline Cube Nov 4, 2022

The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September...

Company Drug

Sinovac’s Varicella Vaccine Receives WHO Pre-Qualification

Fineline Cube Nov 4, 2022

China-based Sinovac has announced receiving pre-qualification (PQ) status from the World Health Organization (WHO) for...

Company Drug

Reforgene Medicine RM-001 Thalassemia Gene Editing

Fineline Cube Nov 4, 2022

China-based Guangzhou Reforgene Medicine Co., Ltd’s in-house developed β-thalassemia gene editing drug RM-001 (HBG gene...

Company Drug

Walvax Biotech Launches Phase IIIb Trial for mRNA COVID-19 Vaccine

Fineline Cube Nov 4, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the initiation of a Phase IIIb...

Company Drug

Guangdong Zhongsheng Initiates Phase III Study for RAY1216 in COVID-19

Fineline Cube Nov 4, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the initiation of a randomized,...

Company

Bloomage Biotech CEO Investigated Over Discounted Share Sales

Fineline Cube Nov 4, 2022

The chairwoman of Chinese medical aesthetics player Bloomage Biotech Corp., Ltd (SHA: 688363), Ms. Zhao...

Policy / Regulatory

NMPA Proposes ‘Drug Online Sales Blacklist’ for Public Feedback

Fineline Cube Nov 4, 2022

The National Medical Products Administration (NMPA) has released a draft proposal for a “Drug Online...

Company Drug

Ascentage Pharma Announces Clinical Advances for Olverembatinib at ASH

Fineline Cube Nov 4, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced the latest clinical development of its olverembatinib (HQP1351), a...

Company Drug

Abbisko Enrolls First Patient in Phase II Study for ABSK091 in Urothelial Carcinoma

Fineline Cube Nov 4, 2022

China-based Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the enrollment of the first patient...

Company Drug

Blue Shield Pharma’s LD013 CAR-T Therapy Approved for Clinical Trials

Fineline Cube Nov 4, 2022

China-based Blue Shield Biotech’s in-house developed LD013, an autologous chimeric antigen receptor (CAR)-T cell therapy,...

Company Deals

Biomed Union Raises RMB 200M in Series B Round for Diagnostic Products

Fineline Cube Nov 4, 2022

Biomed Union (formerly known as Shanghai Biomed-union Biotechnology Co., Ltd), a tumor molecular diagnostic technology...

Company Deals

Yaguo Technology Secures Series A+ Funding for Airway Management Devices

Fineline Cube Nov 4, 2022

Yaguo Technology Co., Ltd, an airway management and respiratory therapy device maker based in Beijing,...

Company Deals

Novatim Immune Therapeutics Raises RMB 500M in First Financing Round

Fineline Cube Nov 4, 2022

China-based tumor immunotherapy developer Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has reportedly raised close to...

Company Deals

Pulnovo Medical Raises ‘Tens of Millions’ in New Financing Round

Fineline Cube Nov 4, 2022

Pulnovo Medical, a pulmonary hypertension (PH) medical device maker based in Wuxi, has reportedly raised...

Company Drug

Akeso Biopharma Completes Enrollment for AK112 Phase III Study

Fineline Cube Nov 4, 2022

China-based Akeso Biopharma (HKG: 9926) has announced the completion of enrollment for its Phase III...

Company Drug

Eccogene Gains FDA Approval for Phase I Study of ECC5004

Fineline Cube Nov 3, 2022

Shanghai-based Eccogene has announced receiving approval from the US FDA to initiate a Phase I...

Company Drug

BeiGene’s Brukinsa Receives EU Marketing Approval for Marginal Zone Lymphoma

Fineline Cube Nov 3, 2022

China-based biotech BeiGene Inc. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced receiving marketing approval from...

Company Deals

Dartsbio Licenses Potential First-in-Class BsAb DS005 to Duality Biologics

Fineline Cube Nov 3, 2022

China-based Dartsbio Pharmaceuticals, Ltd has announced a licensing deal with Duality Biologics, a novel modality...

Company Deals

Fosun Pharma Terminates Equity Transfer Deal with OncoCare Medical

Fineline Cube Nov 3, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the termination of...

Posts pagination

1 … 624 625 626 … 684

Recent updates

  • BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications
  • Lonza and Antharis Therapeutics Forge Exclusive ADC Partnership – Dual-Payload Platform Targets Gastrointestinal Cancers
  • AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035
  • Gilead Sciences Submits sNDA for Once-Weekly Oral Yeztugo PrEP – Potential First Long-Acting Oral HIV Prevention Option
  • Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BMS Secures NMPA Approval for Sotyktu in Psoriatic Arthritis – First Selective TYK2 Inhibitor Expands China Indications

Others

Lonza and Antharis Therapeutics Forge Exclusive ADC Partnership – Dual-Payload Platform Targets Gastrointestinal Cancers

Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Company Drug

Gilead Sciences Submits sNDA for Once-Weekly Oral Yeztugo PrEP – Potential First Long-Acting Oral HIV Prevention Option

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.